NUVL•prnewswire•
Nuvalent Appoints Ron Squarer to Board of Directors
Summary
CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 10, 2025 by prnewswire